Montelukast Teva Uk (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This inhibition prevents leukotrienes—potent inflammatory mediators—from binding to airway smooth muscle and nasal tissues, thereby reducing bronchoconstriction, mucus production, and inflammatory cell infiltration.

The exact dose of Montelukast Teva Uk is set by the prescribing healthcare professional based on the patient’s age, weight, severity of disease, and response to therapy. No universal dosing regimen is provided here; the prescriber tailors the regimen to each individual’s clinical needs.

Safety data for montelukast in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss the decision with their physician.

To request Montelukast Teva Uk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. While it is effective for mild‑to‑moderate asthma and allergic rhinitis, it is generally used as an add‑on therapy rather than a sole replacement for inhaled steroids in severe disease.

Montelukast Teva Uk should be stored at room temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture, direct sunlight, and excessive heat to maintain potency throughout the shelf life.

Montelukast is taken orally as a tablet. The tablet should be swallowed whole with water, typically once daily in the evening, unless the prescriber advises a different schedule. No crushing, chewing, or splitting is recommended unless specifically instructed.

The most serious risks include neuropsychiatric events such as mood changes, depression, or suicidal thoughts, severe allergic reactions like anaphylaxis, and hepatic injury manifested by elevated liver enzymes or hepatitis. Patients should seek immediate medical attention if any of these symptoms develop.

Montelukast should not be used by individuals with a known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe liver disease, and it is generally avoided in those who have experienced serious neuropsychiatric reactions to leukotriene modifiers.